NovoCure - NVCR Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last twelve months. There are currently 2 sell ratings, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NVCR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVCR, but not buy additional shares or sell existing shares.
View NVCR analyst ratings or view top-rated stocks.

6 brokers have issued twelve-month price objectives for NovoCure's shares. Their NVCR share price forecasts range from $50.00 to $130.00. On average, they anticipate the company's share price to reach $87.33 in the next year. This suggests a possible upside of 54.3% from the stock's current price.
View analysts price targets for NVCR or view top-rated stocks among Wall Street analysts.

NovoCure's stock was trading at $73.35 at the start of the year. Since then, NVCR shares have decreased by 22.8% and is now trading at $56.60.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our NVCR earnings forecast.

NovoCure Limited (NASDAQ:NVCR) announced its earnings results on Thursday, February, 23rd. The medical equipment provider reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by $0.04. The medical equipment provider had revenue of $128.43 million for the quarter, compared to the consensus estimate of $127.20 million. NovoCure had a negative trailing twelve-month return on equity of 20.98% and a negative net margin of 17.20%. The business's quarterly revenue was down 3.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.25) EPS.

ETFs with the largest weight of NovoCure (NASDAQ:NVCR) stock in their portfolio include BlueStar Israel Technology ETF (ITEQ), Principal Healthcare Innovators ETF (BTEC), VanEck Israel ETF (ISRA), First Trust Indxx Medical Devices ETF (MDEV), Strategas Global Policy Opportunities ETF (SAGP), ROBO Global Healthcare Technology and Innovation ETF (HTEC), SPDR S&P Health Care Equipment ETF (XHE) and iShares Biotechnology ETF (IBB).

NovoCure issued an update on its fourth quarter 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $128.40 million-$128.40 million, compared to the consensus revenue estimate of $129.14 million.

17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other NovoCure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), Viper Energy Partners (VNOM), Roku (ROKU), Salesforce (CRM) and Block (SQ).

NovoCure trades on the NASDAQ under the ticker symbol "NVCR."

NovoCure's stock is owned by a number of retail and institutional investors. Top institutional investors include Nordwand Advisors LLC (8.68%), Baillie Gifford & Co. (8.40%), Price T Rowe Associates Inc. MD (2.07%), Nordwand Advisors LLC (1.44%), Geode Capital Management LLC (1.29%) and Norges Bank (0.93%). Insiders that own company stock include Asaf Danziger, Ashley Cordova, Ely Benaim, Frank X Leonard, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends.

Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVCR stock can currently be purchased for approximately $56.60.

NovoCure (NASDAQ:NVCR) has a market capitalization of $5.97 billion and generates $537.84 million in revenue each year. The medical equipment provider earns $-92,530,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis.

The company employs 1,320 workers across the globe.

NovoCure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The official website for the company is www.novocure.com. The medical equipment provider can be reached via phone at 441534756700 or via email at investorinfo@novocure.com.